Start-up plans to target epilepsy using gut microbiota
Bloom Science plans to have its proprietary gut bacteria in the clinic for hard-to-treat patients in the next 12-18 months.
In dash to NASH, Immuron targets the gut not the liver
Cookies and milk or cookies and colostrum? Immuron is targeting inflammatory bacteria in the gut with an engineered colostrum formulation, designed to prevent the liver damage that leads to NASH.
Improving the Healthcare Financial Experience to Help Care Flow
Zelis CEO Amanda Eisel shares her perspective on how the company is solving the problems of a fragmented health financial system to benefit all.